Effect of multivalent pneumococcal conjugate vaccine on invasive pneumococcal disease in children

Streptococcus pneumoniae invasive disease surveillance network (spidnet) is a surveillance system for pneumonia in nine regions of seven European countries Five regions use 13 valent pneumococcal conjugate vaccine (pcv13), four regions use 10 and 13 valent vaccines The vaccination rate in six regions is more than 90%, and the rest regions are 67-78% Researchers recently studied the impact of vaccines on the incidence rate of invasive pneumococcal disease in children under 5 years of age The researchers compared the incidence rate of invasive pneumococcal disease between the 4 years after the introduction of PCV13 and PCV10 vaccine and the period before the use of PCV7 vaccine The incidence rate of incidence rate incidence of pneumococcal disease was 0 53 (95% CI 0 43-0 65) after the popularization of the 10 valent and 13 valent vaccine The incidence rate of PCV7 pneumococcal disease was 0.16, 1, 5 and 7F subtype were the proportion of pneumococcal disease incidence rate was 5, and the incidence rate of 6A and 19A subtypes was 1 The incidence rate of the 13 valent vaccine is similar to that of the 7 and 13 price incidence rate The incidence rate of disease caused by the pneumococcal subtype other than the 13 valent vaccine is 1.62 The study showed that the incidence rate of all serotype viruses decreased after using 10 valent and 13 valent vaccines, but the incidence rate of pneumococcal subtypes caused by 13 valent vaccine increased Long term monitoring of pcv10 and pcv13 vaccination programs in children is essential.